Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Status:
Recruiting
Trial end date:
2027-07-31
Target enrollment:
Participant gender:
Summary
A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human BCMA Targeted T Cells
Injection（BCMA CAR-T） Therapy for R/R MM.
Patients will be given a conditioning chemotherapy regimen of fludarabine and
cyclophosphamide followed by a single infusion of BCMA CAR+ T cells.
Phase:
Phase 2
Details
Lead Sponsor:
Hrain Biotechnology Co., Ltd.
Collaborators:
First Affiliated Hospital of Wenzhou Medical University Shanghai Changzheng Hospital